findmyKOL

Shanu Modi, MD

Enriched profile

Breast Medical Oncologist / Assistant Attending, Breast Medicine Service; Section Head, HER2 Positive Breast Cancer · Memorial Sloan Kettering Cancer Center

ORCIDNPI
Region🇺🇸 New York, NY · Northeast · United StatesSpecialtyMedical OncologyFocusHER2/EGFR in Cancer Research+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Shanu Modi is Breast Medical Oncologist / Assistant Attending, Breast Medicine Service; Section Head, HER2 Positive Breast Cancer at Memorial Sloan Kettering Cancer Center. OpenAlex indexes 425 publications with 20,413 citations (h-index 61); ClinicalTrials.gov lists 6 registered studies with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 1 Sept 2026

Shanu Modi, MD, is Breast Medical Oncologist / Assistant Attending, Breast Medicine Service at Memorial Sloan Kettering Cancer Center. The public record shows 425 publications with 20,413 citations (h-index 61), centered on HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 18 companies.

  • Most recent indexed publication: 2026 · Cancer discovery
  • Top research focus: HER2/EGFR in Cancer Research
  • 6 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 18 companies

Generated from the cited public record · current as of 1 Sept 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Breast Cancer6 trialsBreast Neoplasms, Male1 trial

Research focus

OpenAlex concept fingerprint
HER2/EGFR in Cancer ResearchAdvanced Breast Cancer TherapiesCancer Treatment and PharmacologyBreast Cancer Treatment StudiesMonoclonal and Polyclonal Antibodies Research

Drugs & molecules

across trials, industry payments and publications
Enhertugeneric · TrastuzumabClinical trialsIndustry payments64Publications21Trodelvygeneric · SacituzumabClinical trialsIndustry payments10Publications1Perjetageneric · PertuzumabClinical trialsIndustry payments10Publications

Works with

trial sponsors and companies reporting payments
AstraZeneca Pharmaceuticals LPClinical trialsIndustry payments37AstraZeneca UK LimitedClinical trialsIndustry payments28Daiichi Sankyo Inc.Clinical trialsIndustry payments19

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
425publications

Distinct works indexed by OpenAlex, matched via ORCID; 14 in PubMed.

20,413citations

Total citations across indexed works.

61h-index

Hirsch index (OpenAlex). i10-index 159.

Clinical & industry

trials, payments and federal funding
6clinical trials

Investigator role on registered studies.

View trials
18companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 1 Sept 2026

Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:

3 more trial records behind the reveal.Reveal →

Industry payments

Updated 1 Sept 2026

18 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    100%
    Aromatase Inhibitor58.5%
    Anastrozole57%Letrozole31%Exemestane12%
    Part D<11 patients
    Kinase inhibitor20.9%
    Ibrance40%Verzenio33%Kisqali27%
    Part D<11 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Congress activity

Updated 1 Sept 2026

144 congress contributions (2006–2026) across AACR, ASCO, ESMO, SABCS per OpenAlex. The most recent:

Publications

Updated 1 Sept 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 1 Sept 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 1 Sept 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/shanu-modi-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • ResearchGate

    researchgate.net/profile/Shanu-Modi

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net

Mentions by others

where others cite or feature them
  • LinkedIn

    linkedin.com/posts/memorial-sloan-kettering-cancer-center_cancerstraighttalk-activity-6975558885621260288-Z6TD

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • LinkedIn

    linkedin.com/posts/memorial-sloan-kettering-cancer-center_dr-shanu-modi-a-breast-medical-oncologist-activity-7390055263455838209-f6dB

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • Other

    mskcc.org/cancer-care/doctors/shanu-modi

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org
3 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 1 Sept 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Breast Cancer Research Fellowship

    Memorial Sloan Kettering Cancer Center

    2005
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com
  • MD

    University of Alberta

    1995
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org
  • Internal Medicine residency

    University of Alberta

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org
  • Board Certified

    Medical Oncology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org

Editorial & leadership roles

journal and society appointments
  • Chair/Member

    ASCO Scientific Program Committee for HER2 Positive Breast Cancer

    2016
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emedevents.com
  • Member

    ASCO Grants Selection Committee

    2015
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emedevents.com
  • Section Head

    HER2 Positive Breast Cancer, Breast Medicine Service, MSKCC

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
2 more media items behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.